We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
Read MoreHide Full Article
Simulations Plus, Inc (SLP - Free Report) reported third-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 19 cents per share, which declined 9.5% on a year-over-year basis. The figure, however, topped the Zacks Consensus Estimate by 18.8%.
The top line increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology & Pharmacometrics (CPP) and Cheminformatics business units. Continued momentum seen in ADMET Predictor and MonolixSuite platforms was another driver. The top line beat the Zacks Consensus Estimate by 3.4%.
SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value. The last dividend of 6 cents per share will be disbursed on Aug 5, 2024, to shareholders on record as of Jul 29, 2024.
In the past year, SLP's shares have lost 3.4% compared with the sub-industry’s growth of 31.2%.
Image Source: Zacks Investment Research
Quarter in Details
Fiscal third-quarter revenues from Software (64% of total quarterly revenues) increased 12% year over year to $11.9 million.
Sales of MonolixSuite were up 13%. GastroPlus and ADMET Predictor offerings sales saw an increase of 7% and 15% year over year, respectively.
The renewal rate for commercial customers came in at 93% (based upon fees) and 86% (based on accounts) compared with 96% and 87% in the prior quarter, respectively.
Services’ revenues (36%) improved 18% to $6.6 million. The segment’s top line gained from higher revenues from Quantitative Systems Pharmacology (QSP) and Clinical Pharmacology & Pharmacometrics (CPP) business units.
Sales of PBPK unit were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. QSP and CPP sales saw an increase of 49% and 27% year over year, respectively. QSP unit is gaining from increasing immunology and cancer model projects.
Services’ backlog was $19.6 million at the end of the reported quarter, up 24.8% year over year.
Operating Details
The gross margin in the quarter under review was 71% compared with 82% in the prior-year quarter. The Software segment’s gross margin came in at 88% compared with 91% in the prior-year quarter. Services’ gross margin was 41%, down from 63%.
Total operating expenses, as a percentage of revenues, were 61% compared with 57% a year ago.
The operating income margin was 10% compared with 25% a year ago. Adjusted EBITDA margin came in at 31%, a decrease from 40% prior-year quarter.
Balance Sheet
As of May 31, 2024, cash and short-term investments were $119 million compared with $108.5 million as of Feb 29, 2024.
Outlook
For fiscal 2024, Simulations Plus expects revenues to be between $69 million and $72 million. This suggests an increase of 15-20% from fiscal 2023 revenues. Earlier, the company had projected revenues to be in the range of $66-$69 million. The company expects $3 million in revenue contribution from the Pro-ficiency Holdings acquisition and the creation of the new Clinical Simulations and Medical Communications business segment.
The company projects Software and Services to comprise 55-60% and 40-45% of revenues, respectively. SLP estimates adjusted earnings per share to be between 54 cents and 56 cents.
SLP estimates GAAP EPS to be between 46-48 cents compared with the earlier guided range of 66-68 cents per share. The company’s GAAP numbers include the impact of acquisition-related charges.
Currently, Simulations Plus carries a Zacks Rank #4 (Sell).
The Zacks Consensus Estimate for NVDA’s fiscal 2024 EPS is pegged at $2.68. The long-term earnings growth rate is 37.6%. NVDA’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 18.4%. Shares of NVDA have soared 189.2% in the past year.
The Zacks Consensus Estimate for WWD’s fiscal 2024 EPS has increased 6.5% in the past 60 days to $5.88. Woodward’s earnings beat the Zacks Consensus Estimate in all of the last four quarters. The average earnings surprise is 26.1%. Shares of WWD have soared 45.5% in the past year.
The Zacks Consensus Estimate for ANET’s 2024 EPS is pegged at $7.92, indicating growth of 14.1% from the year-ago levels. ANET’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.4%. The long-term earnings growth rate is 16.1%. Shares of ANET have rallied 123.2% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
Simulations Plus, Inc (SLP - Free Report) reported third-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 19 cents per share, which declined 9.5% on a year-over-year basis. The figure, however, topped the Zacks Consensus Estimate by 18.8%.
The top line increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology & Pharmacometrics (CPP) and Cheminformatics business units. Continued momentum seen in ADMET Predictor and MonolixSuite platforms was another driver. The top line beat the Zacks Consensus Estimate by 3.4%.
SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value. The last dividend of 6 cents per share will be disbursed on Aug 5, 2024, to shareholders on record as of Jul 29, 2024.
In the past year, SLP's shares have lost 3.4% compared with the sub-industry’s growth of 31.2%.
Image Source: Zacks Investment Research
Quarter in Details
Fiscal third-quarter revenues from Software (64% of total quarterly revenues) increased 12% year over year to $11.9 million.
Sales of MonolixSuite were up 13%. GastroPlus and ADMET Predictor offerings sales saw an increase of 7% and 15% year over year, respectively.
The renewal rate for commercial customers came in at 93% (based upon fees) and 86% (based on accounts) compared with 96% and 87% in the prior quarter, respectively.
Services’ revenues (36%) improved 18% to $6.6 million. The segment’s top line gained from higher revenues from Quantitative Systems Pharmacology (QSP) and Clinical Pharmacology & Pharmacometrics (CPP) business units.
Sales of PBPK unit were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. QSP and CPP sales saw an increase of 49% and 27% year over year, respectively. QSP unit is gaining from increasing immunology and cancer model projects.
Services’ backlog was $19.6 million at the end of the reported quarter, up 24.8% year over year.
Operating Details
The gross margin in the quarter under review was 71% compared with 82% in the prior-year quarter. The Software segment’s gross margin came in at 88% compared with 91% in the prior-year quarter. Services’ gross margin was 41%, down from 63%.
Total operating expenses, as a percentage of revenues, were 61% compared with 57% a year ago.
The operating income margin was 10% compared with 25% a year ago. Adjusted EBITDA margin came in at 31%, a decrease from 40% prior-year quarter.
Balance Sheet
As of May 31, 2024, cash and short-term investments were $119 million compared with $108.5 million as of Feb 29, 2024.
Outlook
For fiscal 2024, Simulations Plus expects revenues to be between $69 million and $72 million. This suggests an increase of 15-20% from fiscal 2023 revenues. Earlier, the company had projected revenues to be in the range of $66-$69 million. The company expects $3 million in revenue contribution from the Pro-ficiency Holdings acquisition and the creation of the new Clinical Simulations and Medical Communications business segment.
The company projects Software and Services to comprise 55-60% and 40-45% of revenues, respectively. SLP estimates adjusted earnings per share to be between 54 cents and 56 cents.
SLP estimates GAAP EPS to be between 46-48 cents compared with the earlier guided range of 66-68 cents per share. The company’s GAAP numbers include the impact of acquisition-related charges.
Currently, Simulations Plus carries a Zacks Rank #4 (Sell).
Stocks to Consider
Some better-ranked stocks worth consideration in the broader technology space are NVIDIA Corporation (NVDA - Free Report) , Arista Networks, Inc. (ANET - Free Report) and Woodward, Inc. (WWD - Free Report) . While NVDA and WWD sport a Zacks Rank #1 (Strong Buy) each, ANET carries a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for NVDA’s fiscal 2024 EPS is pegged at $2.68. The long-term earnings growth rate is 37.6%. NVDA’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 18.4%. Shares of NVDA have soared 189.2% in the past year.
The Zacks Consensus Estimate for WWD’s fiscal 2024 EPS has increased 6.5% in the past 60 days to $5.88. Woodward’s earnings beat the Zacks Consensus Estimate in all of the last four quarters. The average earnings surprise is 26.1%. Shares of WWD have soared 45.5% in the past year.
The Zacks Consensus Estimate for ANET’s 2024 EPS is pegged at $7.92, indicating growth of 14.1% from the year-ago levels. ANET’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.4%. The long-term earnings growth rate is 16.1%. Shares of ANET have rallied 123.2% in the past year.